Emerging actionable targets to treat therapy-resistant colorectal cancers

Abstract

In the last two decades major improvements have been reached in the early diagnosis of colorectal cancer (CRC) and, besides chemotherapy, an ampler choice of therapeutic approaches is now available, including targeted and immunotherapy. Despite that, CRC remains a “big killer” mainly due to the development of resistance to therapies, especially when the disease is diagnosed after it is already metastatic. At the same time, our knowledge of the mechanisms underlying resistance has been rapidly expanding which allows the development of novel therapeutic options in order to overcome it. As far as resistance to chemotherapy is concerned, several contributors have been identified such as: intake/efflux systems upregulation; alterations in the DNA damage response, due to defect in the DNA checkpoint and repair systems; dysregulation of the expression of apoptotic/anti-apoptotic members of the BCL2 family; overexpression of oncogenic kinases; the presence of cancer stem cells; and the composition of the tumoral microenvironment and that of the gut microbiota. Interestingly, several mechanisms are also involved in the resistance to targeted and/or immunotherapy. For example, overexpression and/or hyperactivation and/or amplification of oncogenic kinases can sustain resistance to targeted therapy whereas the composition of the gut microbiota, as well as that of the tumoral niche, and defects in DNA repair systems are crucial for determining the response to immunotherapy. In this review we will make an overview of the main resistance mechanisms identified so far and of the new therapeutic approaches to overcome it.

Keywords

Colorectal cancer / resistance / chemotherapy / target therapy / EGFR / ERBB2 / MET / BRAF / kinase inhibitors / immune checkpoint inhibitors / gut microbiota

References

[1] Siegel RL,Fedewa SA.Colorectal cancer statistics, 2017.CA Cancer J Clin2017;67:177-93

[2] Arnold M,Laversanne M,Jemal A.Global patterns and trends in colorectal cancer incidence and mortality.Gut2017;66:683-91

[3] Colorectal cancer: statistics. Available from: https://www.cancer.net/cancer-types/colorectal-cancer/statistics [Last accessed on 23 Dec 2021]

[4] Yoshino T,Taniguchi H.Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS.Ann Oncol2018;29:44-70

[5] Glynne-Jones R,Tiret E.ESMO Guidelines CommitteeRectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol2018;29:iv263

[6] Benson AB,Al-Hawary MM.NCCN Guidelines insights: colon cancer, version 2.2018.J Natl Compr Canc Netw2018;16:359-69

[7] Hammond WA,Mody K.Pharmacologic resistance in colorectal cancer: a review.Ther Adv Med Oncol2016;8:57-84 PMCID:PMC4699262

[8] Housman G,Heerboth S.Drug resistance in cancer: an overview.Cancers (Basel)2014;6:1769-92 PMCID:PMC4190567

[9] Cerrito MG.Identifying novel actionable targets in colon cancer.Biomedicines2021;9:579 PMCID:PMC8160963

[10] Cremolini C,Antoniotti C.First-line chemotherapy for mCRC-a review and evidence-based algorithm.Nat Rev Clin Oncol2015;12:607-19

[11] Marin JJG,Monte MJ.Cellular mechanisms accounting for the refractoriness of colorectal carcinoma to pharmacological treatment.Cancers (Basel)2020;12:2605 PMCID:PMC7563523

[12] Grant CE,Hipfner DR.Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs.Cancer Res1994;54:357-61

[13] Cao D,Mu Y.The role of MRP1 in the multidrug resistance of colorectal cancer.Oncol Lett2017;13:2471-6 PMCID:PMC5403295

[14] Zhao J,Zhu D.Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer.Med Oncol2014;31:802 PMCID:PMC3890033

[15] Robey RW,Hall MD,Bates SE.Revisiting the role of ABC transporters in multidrug-resistant cancer.Nat Rev Cancer2018;18:452-64 PMCID:PMC6622180

[16] Borst P.Looking back at multidrug resistance (MDR) research and ten mistakes to be avoided when writing about ABC transporters in MDR.FEBS Lett2020;594:4001-11

[17] Gao Q,Xu YM.IRE1α-targeting downregulates ABC transporters and overcomes drug resistance of colon cancer cells.Cancer Lett2020;476:67-74

[18] Read A.The unfolded protein response: an overview.Biology (Basel)2021;10:384 PMCID:PMC8146082

[19] Park SM,So JS.Roles of XBP1s in transcriptional regulation of target genes.Biomedicines2021;9:791 PMCID:PMC8301375

[20] Gu J,Long E.Upregulated OCT3 has the potential to improve the survival of colorectal cancer patients treated with (m)FOLFOX6 adjuvant chemotherapy.Int J Colorectal Dis2019;34:2151-9

[21] Gu J,Li T.Role and mechanism of organic cation transporter 3 in oxaliplatin treatment of colon cancer in vitro and in vivo.Oncol Rep2019;42:1355-64 PMCID:PMC6718976

[22] Safaei R.Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs.Crit Rev Oncol Hematol2005;53:13-23

[23] Martinez-Balibrea E,Musulén E.Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy.Int J Cancer2009;124:2905-10

[24] Sun S,Yang Q,Wang Z.The association between copper transporters and the prognosis of cancer patients undergoing chemotherapy: a meta-analysis of literatures and datasets.Oncotarget2017;8:16036-51 PMCID:PMC5362544

[25] Untereiner AA,Druzhyna N,Hellmich MR.Drug resistance induces the upregulation of H₂S-producing enzymes in HCT116 colon cancer cells.Biochem Pharmacol2018;149:174-85 PMCID:PMC5866167

[26] Leichman CG,Leichman L.Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin.J Clin Oncol1997;15:3223-9

[27] Salonga D,Johnson M.Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.Clin Cancer Res2000;6:1322-7

[28] Santos A,Cresteil T.Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.Clin Cancer Res2000;6:2012-20

[29] Buck E,Gaida MM.Tumor response to irinotecan is associated with CYP3A5 expression in colorectal cancer.Oncol Lett2019;17:3890-8 PMCID:PMC6403523

[30] Zhao Z,Li W.Elevated expression of ERCC6 confers resistance to 5-fluorouracil and is associated with poor patient survival in colorectal cancer.DNA Cell Biol2017;36:781-6

[31] Leguisamo NM,Kalil AN.Base excision repair imbalance in colorectal cancer has prognostic value and modulates response to chemotherapy.Oncotarget2017;8:54199-214 PMCID:PMC5589573

[32] Mishra B,Zhao H.Discovery of a novel DNA polymerase inhibitor and characterization of its antiproliferative properties.Cancer Biol Ther2019;20:474-86 PMCID:PMC6422523

[33] Jover R,Castells A.Gastrointestinal Oncology Group of the Spanish Gastroenterological AssociationThe efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status.Eur J Cancer2009;45:365-73

[34] Sargent DJ,Monges G.Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.J Clin Oncol2010;28:3219-26 PMCID:PMC2903323

[35] Alex AK,Coudry R.Response to chemotherapy and prognosis in metastatic colorectal cancer with DNA deficient mismatch repair.Clin Colorectal Cancer2017;16:228-39

[36] Oliveira AF,Furtado I.Review of PD-1/PD-L1 inhibitors in metastatic dMMR/MSI-H colorectal cancer.Front Oncol2019;9:396 PMCID:PMC6527887

[37] Hafner A,Jambhekar A.The multiple mechanisms that regulate p53 activity and cell fate.Nat Rev Mol Cell Biol2019;20:199-210

[38] Carethers JM.Genetics and genetic biomarkers in sporadic colorectal cancer.Gastroenterology2015;149:1177-90.e3 PMCID:PMC4589489

[39] Kandioler D,Kappel S.p53 Research Group and the Austrian Breast and Colorectal Study Group (ABCSG)TP53 mutational status and prediction of benefit from adjuvant 5-fluorouracil in stage III colon cancer patients.EBioMedicine2015;2:825-30 PMCID:PMC4563117

[40] Pilat N,Längle F.Assessing the TP53 marker type in patients treated with or without neoadjuvant chemotherapy for resectable colorectal liver metastases: a p53 Research Group study.Eur J Surg Oncol2015;41:683-9

[41] Grassilli E,Federzoni E.A kinase-directed RNAi screen identifies GSK-3b/a as a target to overcome drug resistance of p53-null colon cancer cells.Clin Cancer Res2010;16 supplement:A5

[42] Panchal NK.A serine/threonine protein PIM kinase as a biomarker of cancer and a target for anti-tumor therapy.Life Sci2020;255:117866

[43] Ferreira BI,Link W.Tribbles pseudokinases in colorectal cancer.Cancers (Basel)2021;13:2825 PMCID:PMC8201230

[44] Xiao T,Wang W,Xiao Z.Targeting EphA2 in cancer.J Hematol Oncol2020;13:114 PMCID:PMC7433191

[45] Buckens OJ,Giovannetti E.The role of Eph receptors in cancer and how to target them: novel approaches in cancer treatment.Expert Opin Investig Drugs2020;29:567-82

[46] Reilly NM,Di Nicolantonio F.Exploiting DNA repair defects in colorectal cancer.Mol Oncol2019;13:681-700 PMCID:PMC6441925

[47] Fathi Maroufi N, Rashidi MR, Vahedian V, Akbarzadeh M, Fattahi A, Nouri M. Therapeutic potentials of Apatinib in cancer treatment: possible mechanisms and clinical relevance.Life Sci2020;241:117106

[48] Grassilli E,Federzoni E.Inhibition of GSK3B bypass drug resistance of p53-null colon carcinomas by enabling necroptosis in response to chemotherapy.Clin Cancer Res2013;19:3820-31

[49] Grassilli E,Bonomo S.GSK3A is redundant with GSK3B in modulating drug resistance and chemotherapy-induced necroptosis.PLoS One2014;9:e100947 PMCID:PMC4077702

[50] Grassilli E,Cialdella A.A novel oncogenic BTK isoform is overexpressed in colon cancers and required for RAS-mediated transformation.Oncogene2016;35:4368-78 PMCID:PMC4994017

[51] Lavitrano M,Bonomo S.BTK inhibitors synergise with 5-FU to treat drug-resistant TP53-null colon cancers.J Pathol2020;250:134-47

[52] Sala L,Riva G.Specific expression of a new bruton tyrosine kinase isoform (p65BTK) in the glioblastoma gemistocytic histotype.Front Mol Neurosci2019;12:2 PMCID:PMC6353843

[53] Grassilli E,Bonomo S,Conconi D.p65BTK is a novel biomarker and therapeutic target in solid tumors.Front Cell Dev Biol2021;9:690365 PMCID:PMC8215537

[54] Giordano F,Cortinovis D.p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.J Exp Clin Cancer Res2019;38:260 PMCID:PMC6570906

[55] Zhang L,Park BH,Vogelstein B.Role of BAX in the apoptotic response to anticancer agents.Science2000;290:989-92

[56] Manoochehri M,Bandehpour M.Down-regulation of BAX gene during carcinogenesis and acquisition of resistance to 5-FU in colorectal cancer.Pathol Oncol Res2014;20:301-7

[57] Rampino N,Ionov Y.Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype.Science1997;275:967-9

[58] Wang W,Li L.Andrographolide reversed 5-FU resistance in human colorectal cancer by elevating BAX expression.Biochem Pharmacol2016;121:8-17

[59] Ramesh P.BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy.Apoptosis2020;25:305-20 PMCID:PMC7244464

[60] Raats DA,Steller EJ,Borel-Rinkes IH.Synergistic killing of colorectal cancer cells by oxaliplatin and ABT-737.Cell Oncol (Dordr)2011;34:307-13

[61] Wang X,Yan X.A novel bioavailable BH3 mimetic efficiently inhibits colon cancer via cascade effects of mitochondria.Clin Cancer Res2016;22:1445-58

[62] Ritter V,Klein D,Rudner J.Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy.Cell Death Dis2021;12:694 PMCID:PMC8277842

[63] Kim YS,Park JM.Targeted molecular ablation of cancer stem cells for curing gastrointestinal cancers.Expert Rev Gastroenterol Hepatol2017;11:1059-70

[64] Batlle E.Cancer stem cells revisited.Nat Med2017;23:1124-34

[65] Vallette FM,Lézot F.Dormant, quiescent, tolerant and persister cells: Four synonyms for the same target in cancer.Biochem Pharmacol2019;162:169-76

[66] Oren Y,Cuoco MS.Cycling cancer persister cells arise from lineages with distinct programs.Nature2021;596:576-82

[67] Lenos KJ,Lodestijn SC.Stem cell functionality is microenvironmentally defined during tumour expansion and therapy response in colon cancer.Nat Cell Biol2018;20:1193-202 PMCID:PMC6163039

[68] Cho YH,Yoon JS.5-FU promotes stemness of colorectal cancer via p53-mediated WNT/β-catenin pathway activation.Nat Commun2020;11:5321 PMCID:PMC7578039

[69] Lin CC,Yang MH.Immune adaptation of colorectal cancer stem cells and their interaction with the tumor microenvironment.Front Oncol2020;10:588542 PMCID:PMC7708331

[70] Tang YA,Bao Y.Hypoxic tumor microenvironment activates GLI2 via HIF-1α and TGF-β2 to promote chemoresistance in colorectal cancer.Proc Natl Acad Sci U S A2018;115:E5990-9 PMCID:PMC6042102

[71] Romano G,Bianco MR.The TGF-β pathway is activated by 5-fluorouracil treatment in drug resistant colorectal carcinoma cells.Oncotarget2016;7:22077-91 PMCID:PMC5008345

[72] Hu JL,Lan XL.CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer.Mol Cancer2019;18:91 PMCID:PMC6503554

[73] Ren J,Zhang D.Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal lncRNA H19.Theranostics2018;8:3932-48 PMCID:PMC6071523

[74] Sun LH,Yang ZC.Exosomal miR-21 promotes proliferation, invasion and therapy resistance of colon adenocarcinoma cells through its target PDCD4.Sci Rep2020;10:8271 PMCID:PMC7237414

[75] Zheng X,Wang X.Exosomes derived from 5-fluorouracil-resistant colon cancer cells are enriched in GDF15 and can promote angiogenesis.J Cancer2020;11:7116-26 PMCID:PMC7646166

[76] Zheng X,Li X.Angiogenesis is promoted by exosomal DPP4 derived from 5-fluorouracil-resistant colon cancer cells.Cancer Lett2021;497:190-201

[77] Galdiero MR,Barajon I,Mantovani A.Tumor associated macrophages and neutrophils in cancer.Immunobiology2013;218:1402-10

[78] Tolba MF.Revolutionizing the landscape of colorectal cancer treatment: the potential role of immune checkpoint inhibitors.Int J Cancer2020;147:2996-3006

[79] Yu T,Yu Y.Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy.Cell2017;170:548-63.e16 PMCID:PMC5767127

[80] Zhang S,Weng W.Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer.J Exp Clin Cancer Res2019;38:14 PMCID:PMC6327560

[81] Chen Y,Yu J.Invasive Fusobacterium nucleatum activates beta-catenin signaling in colorectal cancer via a TLR4/P-PAK1 cascade.Oncotarget2017;8:31802-14 PMCID:PMC5458249

[82] Geller LT,Danino T.Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine.Science2017;357:1156-60 PMCID:PMC5727343

[83] Iida N,Stewart CA.Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment.Science2013;342:967-70 PMCID:PMC6709532

[84] Ooki A,Yamaguchi K.Immunotherapy in colorectal cancer: current and future strategies.J Anus Rectum Colon2021;5:11-24 PMCID:PMC7843143

[85] Rankin A,Erlich R.Broad detection of alterations predicted to confer lack of benefit from EGFR antibodies or sensitivity to targeted therapy in advanced colorectal cancer.Oncologist2016;21:1306-14 PMCID:PMC5189622

[86] Raskov H,Troelsen J,Gögenur I.Driver gene mutations and epigenetics in colorectal cancer.Ann Surg2020;271:75-85

[87] Misale S,Sartore-Bianchi A,Bardelli A.Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution.Cancer Discov2014;4:1269-80

[88] Bardelli A,Bertotti A.Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.Cancer Discov2013;3:658-73 PMCID:PMC4078408

[89] Troiani T,Napolitano S.Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells.Clin Cancer Res2013;19:6751-65

[90] Song N,Zhang J.Cetuximab-induced MET activation acts as a novel resistance mechanism in colon cancer cells.Int J Mol Sci2014;15:5838-51 PMCID:PMC4013599

[91] Song N,Liu S.Dual inhibition of MET and SRC kinase activity as a combined targeting strategy for colon cancer.Exp Ther Med2017;14:1357-66 PMCID:PMC5526150

[92] Jia Y,Wang J.c-MET inhibition enhances the response of the colorectal cancer cells to irradiation in vitro and in vivo.Oncol Lett2016;11:2879-85 PMCID:PMC4812355

[93] Rimassa L,Pietrantonio F.Phase II study of tivantinib and cetuximab in patients with KRAS wild-type metastatic colorectal cancer with acquired resistance to EGFR inhibitors and emergence of MET overexpression: lesson learned for future trials with EGFR/MET dual inhibition.Clin Colorectal Cancer2019;18:125-32.e2

[94] Eng C,Hart LL.A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy.Int J Cancer2016;139:177-86 PMCID:PMC5071720

[95] Craig SG,Humphries MP.Orthogonal MET analysis in a population-representative stage II-III colon cancer cohort: prognostic and potential therapeutic implications.Mol Oncol2021;15:3317-28 PMCID:PMC8637556

[96] Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer.Nature2012;48:330-7

[97] Bertotti A,Galimi F.A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.Cancer Discov2011;1:508-23

[98] Kavuri SM,Galimi F.HER2 activating mutations are targets for colorectal cancer treatment.Cancer Discov2015;5:832-41 PMCID:PMC4527087

[99] Cremolini C,Moretto R.Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study.Ann Oncol2017;28:3009-14

[100] Bregni G,Sobrero A.HER2 amplification and Anti-EGFR sensitivity in advanced colorectal cancer.JAMA Oncol2019;5:605-6

[101] Yonesaka K,Okamoto I.Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.Sci Transl Med2011;3:99ra86 PMCID:PMC3268675

[102] Mohan S,Ulz P.Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing.PLoS Genet2014;10:e1004271 PMCID:PMC3967949

[103] Sartore-Bianchi A,Martino C.Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.Lancet Oncol2016;17:738-46

[104] Hainsworth JD,Swanton C.Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study.J Clin Oncol2018;36:536-42

[105] Nakamura Y,Kato T.TRIUMPH: primary efficacy of a phase II trial of trastuzumab (t) and pertuzumab (p) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumor tissue circulating tumor DNA (ctDNA): a GOZILA sub-study.Ann Oncol2019;30:v199-200

[106] Strickler J,Ou F.Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): initial results from the MOUNTAINEER trial.Ann Oncol2019;30:v200

[107] Mauri G,Siena S,Sartore-Bianchi A.The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer.Ann Oncol2020;31:1135-47

[108] Guarini C,Pezzicoli G.Beyond RAS and BRAF: HER2, a new actionable oncotarget in advanced colorectal cancer.Int J Mol Sci2021;22:6813 PMCID:PMC8268006

[109] Mangiapane LR,Turdo A.PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells.Gut2022;71:119-28

[110] Pietrantonio F,Siravegna G.Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer.Clin Cancer Res2017;23:2414-22

[111] Baselga J.The EGFR as a target for anticancer therapy - focus on cetuximab.Eur J Cancer2001;37:16-22

[112] Vitiello PP,Martini G.Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.J Exp Clin Cancer Res2019;38:41 PMCID:PMC6350302

[113] Hasbal-Celikok G,Altiparmak-Ulbegi G.Identification of AKT1/β-catenin mutations conferring cetuximab and chemotherapeutic drug resistance in colorectal cancer treatment.Oncol Lett2021;21:209 PMCID:PMC7816326

[114] Martini G,Vitiello PP.EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving antiepidermal growth factor receptor therapy in colorectal cancer.Mol Cancer Ther2019;18:845-55

[115] Kopetz S,Chan E.PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors.J Clin Oncol2010;28:3534-3534

[116] Hyman DM,Subbiah V.Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations.N Engl J Med2015;373:726-36 PMCID:PMC4971773

[117] Kopetz S,Chan E.Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer.J Clin Oncol2015;33:4032-8 PMCID:PMC4669589

[118] Prahallad A,Huang S.Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.Nature2012;483:100-3

[119] Corcoran RB,Turke AB.EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.Cancer Discov2012;2:227-35 PMCID:PMC3308191

[120] Yao Z,Su W.RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling.Nat Med2019;25:284-91 PMCID:PMC6404779

[121] Kawakami H,Pal K,Mukhopadhyay D.Mutant BRAF upregulates MCL-1 to confer apoptosis resistance that is reversed by MCL-1 antagonism and cobimetinib in colorectal cancer.Mol Cancer Ther2016;15:3015-27 PMCID:PMC5136313

[122] Chen G,Gao X.Wnt/β-catenin pathway activation mediates adaptive resistance to BRAF inhibition in colorectal cancer.Mol Cancer Ther2018;17:806-13 PMCID:PMC5882543

[123] Grbčić P,Gamberi T,Sedić M.Proteomic profiling of BRAFV600E mutant colon cancer cells reveals the involvement of nucleophosmin/c-Myc axis in modulating the response and resistance to BRAF inhibition by vemurafenib.Int J Mol Sci2021;22:6174 PMCID:PMC8228139

[124] Yang H,Kolinsky K.Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.Cancer Res2012;72:779-89

[125] Atreya CE,Bendell JC.Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC).J Clin Oncol2015;33:103

[126] Tabernero J,Guren TK.Phase 2 results: encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC).J Clin Oncol34:3544

[127] Yaeger R,O'Reilly EM.Pilot trial of combined BRAF and EGFR inhibition in BRAF mutant metastatic colorectal cancer patients.Clin Cancer Res2015;21:1313-20 PMCID:PMC5546416

[128] Yaeger R,Hyman DM.Mechanisms of acquired resistance to BRAF V600E inhibition in colon cancers converge on RAF dimerization and are sensitive to its inhibition.Cancer Res2017;77:6513-23 PMCID:PMC5712250

[129] Long GV,Gogas H.Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.N Engl J Med2014;371:1877-88

[130] Robert C,Schachter J.Improved overall survival in melanoma with combined dabrafenib and trametinib.N Engl J Med2015;372:30-9

[131] Halle BR.Defining and targeting BRAF mutations in solid tumors.Curr Treat Options Oncol2021;22:30

[132] Tan J,Zhu G,Xing M.TERT promoter mutation determines apoptotic and therapeutic responses of BRAF-mutant cancers to BRAF and MEK inhibitors: achilles heel.Proc Natl Acad Sci U S A2020;117:15846-51 PMCID:PMC7355024

[133] Kopetz S,Yaeger R.Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer.N Engl J Med2019;381:1632-43

[134] Kopetz S,Morris VK.Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406).J Clin Oncol2021;39:285-94 PMCID:PMC8462593

[135] Van Cutsem E,Grothey A.Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E-mutant metastatic colorectal cancer: safety lead-in results from the phase III BEACON colorectal cancer study.J Clin Oncol2019;37:1460-9 PMCID:PMC7370699

[136] Tabernero J,Van Cutsem E.Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study.J Clin Oncol2021;39:273-84 PMCID:PMC8078423

[137] Eng C.BRAF mutation in colorectal cancer: an enigmatic target.J Clin Oncol2021;39:259-61

[138] Lapeyre-prost A,Pernot S.Immunomodulatory activity of VEGF in cancer.Int Rev Cell Mol Biol2017;330:295-342

[139] Grassi E,Papiani G,Gazzaneo F.Current therapeutic strategies in BRAF-mutant metastatic colorectal cancer.Front Oncol2021;11:601722 PMCID:PMC8262685

[140] Rosen LS,Burkes RL.Bevacizumab in colorectal cancer: current role in treatment and the potential of biosimilars.Target Oncol2017;12:599-610 PMCID:PMC5610666

[141] Torben Frøstrup H, Qvortrup C, Pfeiffer P. Angiogenesis inhibitors for colorectal cancer. A review of the clinical data.Cancers2021;13,1031

[142] de Gramont A,Schmoll H.Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.Lancet Oncol2012;13:1225-33

[143] Belotti D,Taraboletti G.Alternative vascularization mechanisms in tumor resistance to therapy.Cancers2021;13:1912 PMCID:PMC8071410

[144] Knopik-skrocka A,Jarmołowska-jurczyszyn D.Tumor blood vessels and vasculogenic mimicry - current knowledge and searching for new cellular/molecular targets of anti-angiogenic therapy.Adv Cell Biol2017;5:50-71

[145] Lai E,Scartozzi M.Are all anti-angiogenic drugs the same in the treatment of second-line metastatic colorectal cancer?.Front Oncol2021;11:637823 PMCID:PMC8141840

[146] Hecht JR,Dakhil S.SPIRITT: a randomized, multicenter, phase II Study of panitumumab with FOLFIRI and bevacizumab with FOLFIRI as second-line treatment in patients with unresectable wild type KRAS metastatic colorectal cancer.Clin Colorectal Cancer2015;14:72-80

[147] Hu-Lowe DD,Zhang L.Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies.Cancer Res2011;71:1362 PMCID:PMC3269003

[148] Ciardiello D,Tabernero J.Clinical development of therapies targeting TGFβ: current knowledge and future perspectives.Ann Oncol2020;31:1336-49

[149] Hanahan D.Signaling vascular morphogenesis and maintenance.Science1997;277:48-50

[150] Goede V,Neuneier J.Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy.Br J Cancer2010;103:1407-14 PMCID:PMC2990609

[151] Rigamonti N,Keklikoglou I,Leow CC.Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade.Cell Rep2014;8:696-706

[152] Kienast Y,Scheuer W.Ang-2-VEGF-A crossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy.Clin Cancer Res2013;19:6730-40

[153] Park JS,Han S.Normalization of tumor vessels by Tie2 activation and Ang2 inhibition enhances drug delivery and produces a favorable tumor microenvironment.Cancer Cell2016;30:953-67

[154] Krzystek-Korpacka M,Kapturkiewicz B,Gamian A.Profiles of circulating inflammatory cytokines in colorectal cancer (CRC), high cancer risk conditions, and health are distinct. Possible implications for CRC screening and surveillance.Cancer Lett2013;337:107-14

[155] Łukaszewicz-Zając M.Circulating biomarkers of colorectal cancer (CRC)-their utility in diagnosis and prognosis.J Clin Med2021;10:2391 PMCID:PMC8199026

[156] Cazzaniga ME,Capici S,Riva F.Metronomic chemotherapy.Cancers (Basel)2021;13:2236 PMCID:PMC8125766

[157] Simkens LHJ,May A.Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.Lancet2015;385:1843-52

[158] Llosa NJ,Tam A.The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints.Cancer Discov2015;5:43-51 PMCID:PMC4293246

[159] Giannakis M,Shukla SA.Genomic correlates of immune-cell infiltrates in colorectal carcinoma.Cell Rep2016;15:857-65 PMCID:PMC4850357

[160] Overman MJ,Leach JL.Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.Lancet oncol2017;18:1182-91 PMCID:PMC6207072

[161] André T,Kim TW.KEYNOTE-177 InvestigatorsPembrolizumab in microsatellite-instability-high advanced colorectal cancer.N Engl J Med2020;383:2207-18

[162] LAG3-PD-1 combo impresses in melanoma.Cancer Discov2021;11:1605-6

[163] Yu X,Chen X.Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy.MAbs2019;11:1139-48 PMCID:PMC6748621

[164] Tang K,Song Y.Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy.J Hematol Oncol2021;14:68 PMCID:PMC8061021

[165] Le Naour J, Galluzzi L, Zitvogel L, Kroemer G, Vacchelli E. Trial watch: IDO inhibitors in cancer therapy.Oncoimmunology2020;9:1777625 PMCID:PMC7466863

[166] Prendergast GC,Mondal A,Muller AJ.Indoleamine 2,3-dioxygenase and its therapeutic inhibition in cancer.Int Rev Cell Mol Biol2018;336:175-203 PMCID:PMC6054468

[167] Voron T,Pernot S.Control of the immune response by pro-angiogenic factors.Front Oncol2014;4:70 PMCID:PMC3980099

[168] Wang Q,Di W.Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models.Cancer Immunol Immunother2020;69:1781-99

[169] Anfossi S.Gut microbiota: a new player in regulating immune- and chemo-therapy efficacy.Cancer Drug Resist2020;3:356-70 PMCID:PMC7556722

[170] Vétizou M,Daillère R.Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.Science2015;350:1079-84 PMCID:PMC4721659

[171] Sivan A,Hubert N.Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.Science2015;350:1084-9 PMCID:PMC4873287

[172] Gopalakrishnan V,Nezi L.Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.Science2018;359:97-103 PMCID:PMC5827966

[173] Matson V,Bao R.The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.Science2018;359:104-8 PMCID:PMC6707353

[174] Routy B,Derosa L.Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.Science2018;359:91-7